(NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health ...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its ...
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway ...
The Bangladesh Premier League (BPL) has survived a series of stumbles and mis-steps to get into its 12th year. As it begins, there are serious questions about the tournament's integrity, the quality ...
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for ...
Atai Life Sciences announced positive results from a Phase 2a study of BPL-003, a synthetic intranasal treatment for alcohol use disorder (AUD), showing that a single dose combined with relapse ...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 ...
Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results